Gnanasakthy A, Barrett A, Norcross L, D’Alessio D, Romano (DeMuro) C. Use of patient and investigator global impression scales: a review of Food and Drug Administration–approved labeling, 2009 to 2019. Value Health. 2021 Jul;24(7):1016-23. doi: 10.1016/j.jval.2021.01.005
Banjara B, Emory LA, Poudel N, Qian J, Ngorsuraches S. Patients' preferences for antihyperglycemic medications for type 2 diabetes: a systematic review of discrete choice experiment. Poster presented at the Virtual ISPOR 2021 Conference; May 17, 2021. [abstract] Value Health. 2021 Jun; 24(Suppl 1):S86. doi: 10.1016/j.jval.2021.04.444
Herring WL, Mladsi DM. Equal value of life-years gained: comparison of methodologies for a cohort Markov model. Poster presented at the Virtual ISPOR 2021 Conference; May 2021. [abstract] Value Health. 2021 Jun; 24(Suppl 1):S176.
Mansfield C, Nalysnyk L, Joshi D, Coulter J, Pulikottil-Jacob R. Patient and parent preferences for symptom control in ASMD Type B and A/B using best-worst scaling methodology. Poster presented at the Virtual ISPOR 2021 Conference; May 2021. [abstract] Value Health. 2021 May; 24(5).
Ciarametaro M, Houghton K, Wamble D, Dubois R. The dollar or disease burden: caps on health care spending may save money, but at what “cost” to patients? Value Health. 2021 Mar;24(3):388-96. doi: 10.1016/j.jval.2020.10.024v
Appukkuttan S, Farej R, Miles L, Purser M, Wen L. Budget impact analysis of darolutamide for treatment of nonmetastatic castration-resistant prostate cancer. J Manag Care Spec Pharm. 2021 Feb;27(2):166-74. doi: 10.18553/jmcp.2020.20330
Mauskopf J, Masaquel C, Huang L. Evaluating vaccination programs that prevent diseases with potentially catastrophic health outcomes: how can we capture the value of risk reduction? Value Health. 2021 Jan 1;24(1):86-90.
Aronsson M, Dunton K, Hawe E, Wolowacz S, Quoraishi S, Durrington P, Ray KK, Bilitou A. Building a cost-effectiveness MODEL framework from a payer's perspective to assess NOVEL treatments in primary hypercholesterolaemia and MIXED dyslipidaemia: challenges in a world of LDL-C lowering. Poster presented at the Virtual ISPOR Europe 2020 Conference; November 2020. [abstract] Value Health. 2020 Dec; 23(S2).
Dorgali MV, Longo A, Vass C, Shields G, Harrison R, Boeri M. Exploring Antimicrobial Resistance (AMR) from a societal perspective: preferences and welfare impacts in the United Kingdom. Poster presented at the Virtual ISPOR Europe 2020 Conference; November 2020. [abstract] Value Health. 2020 Dec; 23(S2).
D'Souza VK, Alderson D. Early access and targeted supply considerations in emerging markets. Poster presented at the Virtual ISPOR Europe 2020 Conference; November 16, 2020. [abstract] Value Health. 2020 Dec; 23(S2):S656. doi: 10.1016/j.jval.2020.08.1524
Turner AJ, Vass C. Matching techniques in stated preferences for health. Presented at the Virtual ISPOR Europe 2020 Conference; November 9, 2020. [abstract] Value Health. 2020 Dec; 23(Supplement 2):S758. doi: 10.1016/j.jval.2020.08.2086
Stevenson A, Gildea L. A Medtech roadmap: new routes to market access in the UK NHS. Poster presented at the Virtual ISPOR Europe 2020 Conference; November 2020. [abstract] Value Health. 2020 Dec; 23(S2):S576.
Vass C, Rigby D, Payne K. Watching ME watching you: understanding the effect of experimental setting on stated preferences. Poster presented at the Virtual ISPOR Europe 2020 Conference; November 2020. [abstract] Value Health. 2020 Dec; 23(S2).
Noon K, Costello J, Krieger T, Rothwell B, Pearson I. Utility weight considerations in NICE immune checkpoint inhibitor oncology appraisals. Poster presented at the Virtual ISPOR Europe 2020 Conference; November 2020. [abstract] Value Health. 2020 Dec; 23(S2).
Carrico J, La EM, Talbird SE, Chen YT, Nyaku MK, Carias C, Marshall GS, Roberts CS. Economic impact of routine childhood immunization in the 2017 United States birth cohort. Presented at the Virtual ISPOR Europe 2020 Conference; November 2020. [abstract] Value Health. 2020 Dec 1; 23(Supplement 2):S427. doi: 10.1016/j.jval.2020.08.039
Bektas M, Copley-Merriman C, Khan S, Sarda SP, Shammo JM. Paroxysmal nocturnal hemoglobinuria: patient journey and burden of disease. J Manag Care Spec Pharm. 2020 Dec;26(12-b Suppl):S8-S14. doi: 10.18553/jmcp.2020.26.12-b.s8
Bektas M, Copley-Merriman C, Khan S, Sarda SP, Shammo JM. Paroxysmal nocturnal hemoglobinuria: role of the complement system, pathogenesis, and pathophysiology. J Manag Care Spec Pharm. 2020 Dec;26(12-b Suppl):S3-8. doi: 10.18553/jmcp.2020.26.12-b.s3
Bektas M, Copley-Merriman C, Khan S, Sarda SP, Shammo JM. Paroxysmal nocturnal hemoglobinuria: current treatments and unmet needs. J Manag Care Spec Pharm. 2020 Dec;26(12-b Suppl):S14-20. doi: 10.18553/jmcp.2020.26.12-b.s14
Shah SN, Hepp Z, Martin S, Harris N, Morgans A. Qualitative analysis of pain in patients with locally advanced or metastatic urothelial cancer. Poster presented at the Virtual ISPOR Europe 2020 Conference; November 2020. [abstract] Value Health. 2020 Dec; 23(S2).
Herring W, Gould I, Haines P, Thompson R, Pemberton-Ross P. Predicted delays in dementia onset for an innovative therapy acting on beta-amyloid in patients with mild cognitive impairment due to Alzheimer's disease. Poster presented at the Virtual ISPOR Europe 2020 Conference; November 16, 2020. [abstract] Value Health. 2020 Dec; 23(S2).
Purser M, Gallagher M, Mladsi D, Weber JM, Andemariam B, Kaye JA, Chawla A. Evaluation of published models in sickle cell disease against key criteria for an economic model for a potentially curative one-time treatment. Poster presented at the Virtual ISPOR Europe 2020 Conference; November 2020. [abstract] Value Health. 2020 Dec; 23(S2). doi: 10.1016/j.jval.2020.08.098
Patterson BJ, Herring WL, van Oorschot D, Curran D, Carrico J, Zhang Y, Ackerson BK, Bruxvoort K, Sy LS, Tseng HF. Incremental clinical and economic impact of recombinant zoster vaccination: real-world data in a budget impact model. J Manag Care Spec Pharm. 2020 Dec;26(12):1567-75. doi: 10.18553/jmcp.2020.20251
Manga N. Applying a normal distribution to costs in probabilistic sensitivity analysis - NOT necessarily a negative outcome. Poster presented at the Virtual ISPOR Europe 2020 Conference; November 2020. [abstract] Value Health. 2020 Dec; 23(S2).
Molnar D, D'Souza V, Martin A. How the disease progression is captured in COPD models? A systematic literature review of disease and economic models. Poster presented at the 2020 Virtual ISPOR Europe; December 2020. [abstract] Value Health. 2020 Nov; 23(S2):S729-30. doi: 10.1016/j.jval.2020.08.1947
Serbin M, Odak S, Macahilig C, Joshi N, Shah A, Ng X, Olson K, Liang GS, Klepitskaya O, Yonan C. Burden of parkinson's disease in a real-world sample of patients with motor fluctuations. Poster presented at the 2020 Virtual AMCP NEXUS; October 2020. [abstract] J Manag Care Spec Pharm. 2020 Oct; 26(10-a):S43. doi: 10.18553/jmcp.2020.26.10-a.s1
Jiang S, Varghese D, Appukkuttan S, Corman S, Kebede N, Gnanasakthy K, Macahilig C, Waldeck R, Hussain A. Real-world incidence and management of adverse events (AEs) in patients with non-metastatic castrate-resistant prostate cancer receiving apalutamide or enzalutamide. Poster presented at the Virtual Journal of Managed Care & Specialty Pharmacy 2020 Conference; October 2020. [abstract] J Manag Care Spec Pharm. 2020 Oct; 26(10-a Suppl):S89. Previously presented at the 2020 Virtual ISPOR Asia Pacific Conference.
Bhattacharya R, Herren K, Poonawalla I, Bunniran S, Bloomfield A, Schwab PE. Comparing medical utilization and cost outcomes in oral versus injectable immunotherapy users with chronic inflammatory joint and skin diseases. J Manag Care Spec Pharm. 2020 Oct;26(10):1246-56. doi: 10.18553/jmcp.2020.26.10.1246
Bassali J, Gould I, Mladsi D, Kaye JA, Shah J, Mehta J. A US budget impact model for selinexor in combination with dexamethasone for the treatment of patients with relapsed or refractory multiple myeloma (RRMM). Poster presented at the 2020 ISPOR Virtual Conference; May 2020. [abstract] Value Health. 2020 May; 23(Suppl 1):S33.
Myers K, Klein K, Mansfield C, Poulos C. A review of the use of comprehension questions in health preference studies. Poster presented at the 2020 ISPOR Virtual Conference; May 2020. [abstract] Value Health. 2020 May 1; 23(Suppl 1):S319-20. doi: 10.1016/j.jval.2020.04.1189
VanderPluym JH, Ramirez-Campos V, Cortez A, Cohen J, Gandhi S, Lewis S, Sweeney C, DeMuro C, Lipton R. Patient-reported outcomes to assess symptoms and effects across all 5 phases of migraine. Poster presented at the 2020 ISPOR Conference (Conference cancelled); May 2020. [abstract] Value Health. 2020 May; 23(Supplement 1):S280.
Vass C, Boeri M, Poulos C. Association between access device and stated preferences for health care. Poster presented at the 2020 ISPOR Virtual Conference; May 2020. [abstract] Value Health. 2020 May 1;. doi: 10.1016/j.jval.2020.04.1183
Poulos C, Vass C, Klein K, Boeri M. Scope tests in health care discrete choice experiments. Poster presented at the 2020 ISPOR Virtual Conference; May 2020. [abstract] Value Health. 2020 May 1; 23(Suppl 1):S320. doi: 10.1016/j.jval.2020.04.094
Poulos C, Hauber B, Mirzaei F, Dilley A, DeMuro C, Fillit HM. A study of preferences for disease-modifying treatments for Alzheimer's Disease. Poster presented at the 2020 ISPOR Virtual Conference; May 2020. [abstract] Value Health. 2020 May 1; 23(Suppl 1):S278. doi: 10.1016/j.jval.2020.04.991
Reynolds M, Odom D, Richardson D, Hollis KA, Zhan L, Mitra D, McRoy L, Bowles S. Benefits and challenges of mobile health applications in prospective studies: learnings from the Madeline Study and literature. Poster presented at the 2020 ISPOR Virtual Conference; May 2020. [abstract] Value Health. 2020 May 1; 23(Suppl 1):S71-2. doi: 10.1016/j.jval.2020.04.1183
Castro C, Mordin M, Islam Z, Tu N, Hackshaw MD, Salas M. A review of non-disease specific health-related quality of life measures with reliability and validity evidence in patients with breast cancer. Poster presented at the 2020 ISPOR Virtual Conference; May 2020. [abstract] Value Health. 2020 May 1; 23(Suppl 1):S81.
Saretsky T, Finelli L, Phillips M, DeMuro C, Lewis S, Norquist J, Monto A, Martin ET, Osborne RH. Measuring Respiratory Syncytial Virus (RSV) symptom intensity and impact in adults: content validity assessment of a Patient-Reported Outcome (PRO) measure: the RSV Infection Intensity and Impact Questionnaire (RSV-IIIQ). Poster presented at the 2020 ISPOR Virtual Conference; May 2020. [abstract] Value Health. 2020 May 1; 23(Supplement 1):S360. doi: 10.1016/j.jval.2020.04.1380
Copley-Merriman C, Yang X, Juniper M, Amin S, Yoo HK, Sen S. Impact of neurofibromatosis type 1 and plexiform neurofibromas on patient-reported health-related quality of life. Poster presented at the 2020 ISPOR Virtual Conference; May 2020. [abstract] Value Health. 2020 May 1; 23(Suppl 1):S344. doi: 10.1016/j.jval.2020.04.371
Meyers J, Hoog M, Mody R, Yu M, Hasenour C, Davis KL. Burden of cardiovascular disease and cardiovascular (CV) risk in patients with Type 2 diabetes mellitus (T2DM): an analysis of a US health insurance database. Poster presented at the 2020 ISPOR Virtual Conference; May 2020. [abstract] Value Health. 2020 May 1; 23(Suppl 1):S115. doi: 10.1016/j.jval.2020.04.371
Banjara B, Willke R, Guerino J, Ngorsuraches S. ISPOR top 10 HEOR trends: results from a best-worst scaling survey. Poster presented at the 2020 ISPOR Virtual Conference; May 16, 2020. [abstract] Value Health. 2020 May; 23(Suppl 1):S313. doi: 10.1016/j.jval.2020.04.1155
Banjara B, Kavookjian J. Interventions including motivational interviewing in adolescents with asthma: a systematic review. Poster presented at the 2020 ISPOR Virtual Conference; May 16, 2020. [abstract] Value Health. 2020 May; 23(Suppl 1):S349. doi: 10.1016/j.jval.2020.04.1331
Mansfield C, Boeri M, Coulter J, Baranowski E, Sparks S, Hamed A. Preferences for genetic tests: trading off speed of diagnosis, availability of treatment, and cost. Poster presented at the 2020 ISPOR Virtual Conference; May 2020. [abstract] Value Health. 2020 May 1; 23(Suppl 1):S345. doi: 10.1016/j.jval.2020.04.094
Filonenko A, Purser M, Mader G, Graham J. Impact of increased utilization of long-acting reversable contraceptive methods among young women on cost and unintended pregnancies (UP) in the United States (US). Poster presented at the 2020 ISPOR Virtual Conference; May 2020. [abstract] Value Health. 2020 May 1; 23(Suppl 1):S153. doi: 10.1016/j.jval.2020.04.371
Parikh RC, Niyazov A, Esterberg E, Arondekar B, Hitchens A, Shahied Arruda L, Obeid E. Real-world patient demographics, treatment patterns and healthcare resource utilization (HRU) among Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Advanced Breast Cancer (ABC) patients with BRCA1/2 Mutations (BRCA1/2MUT). Poster presented at the 2020 ISPOR Virtual Conference; May 2020. [abstract] Value Health. 2020 May 1; 23(Suppl 1):S79. doi: 10.1016/j.jval.2020.04.094
Zhang Y, Herring W. The impact of alternative weighting methodologies on cross-indication value-based pricing estimates. Poster presented at the 2020 ISPOR Virtual Conference; May 2020. [abstract] Value Health. 2020 May 1; 23(Suppl 1):S289. doi: 10.1016/j.jval.2020.04.094
Sutphin J, DiSantostefano R, Leach CA, Hauber B, Mansfield C. Preferences, optimism, and numeracy: an exploration into the use of psychological patient-reported outcome instruments in a preference survey. Presented at the 2020 ISPOR Virtual Conference; May 19, 2020. [abstract] Value Health. 2020 May 1; 23(Suppl 1):S328. doi: 10.1016/j.jval.2020.04.094
Sutphin J, Mansfield C, DiSantostefano R, Klein K, Boeri M. Getting the most out of latent-class analysis in modeling preferences for an interception treatment in Type 1 diabetes. Poster presented at the 2020 ISPOR Virtual Conference; May 2020. [abstract] Value Health. 2020 May 1; 23(Suppl 1):S125. doi: 10.1016/j.jval.2020.04.371
Gnanasakthy A, Barrett A, D'Alessio D, Norcross L. Review of patient and clinician global assessments in PRO labeling (2017-2019). Poster presented at the ISPOR Virtual 2020 Conference; May 2020. [abstract] Value Health. 2020 May 1; 23(Suppl 1):S299. doi: 10.1016/j.jval.2020.04.094
Thach A, Sutphin J, Coulter J, Mansfield C. Preferences for on-demand treatments for Parkinson's disease–related "OFF" episodes: a discrete-choice experiment. Presented at the 2020 ISPOR Virtual Conference; May 18, 2020. [abstract] Value Health. 2020 May 1; 23(Suppl 1):S325. doi: 10.1016/j.jval.2020.04.094
La EM, Talbird SE, Brogan AJ, Davis AE. Budget-impact analysis of ibalizumab in the treatment of US Medicare beneficiaries with multidrug-resistant HIV-1 infection. Poster presented at the 2020 ISPOR Virtual Conference; May 2020. [abstract] Value Health. 2020 May 1; 23(Suppl 1):S174. doi: 10.1016/j.jval.2020.04.371
Yi Z, Mauskopf J, Herring W, Graham J. Challenges in estimating eligible population size in budget-impact analyses for new health care technologies. Poster presented at the 2020 ISPOR Virtual Conference; May 2020. [abstract] Value Health. 2020 May 1; 23(Suppl 1):S288. doi: 10.1016/j.jval.2020.04.371